THE IMMUNOBIOPSY™ COMPANY – BECAUSE EARLY DETECTION IS LIFE™
The Savicell™ Well-Shield™ platform is a blood test inherently designed for the early detection of disease.  
Cancer is our first focus.

Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market.

Metabolic changes in the immune system modulate cell fate and function, influencing immune response outcomes. These energy changes give the immune system the ability (effector function) to attack disease, including cancer.  Diseases produce unique signatures in immune metabolic profiles that ImmunoBiopsy™ uses to distinguish between and within various ailments, such as cancers, autoimmune diseases, and infectious diseases. Savicell’s Liquid ImmunoBiopsy measures the energy changes of the immune system, which are disease-specific, and identifies the ailment.

Savicell

Org chart

Teams

Offices